Charles River updates its research database with addition of new tumor models

Charles River
CRO Charles River updated its Tumor Model Compendium database with the addition of new tumor models for early-stage oncology research. (Charles River)

Charles River Labs has updated its Tumor Model Compendium database with the addition of new tumor models for early-stage oncology research.

The latest updates include gastric and liver models, and new molecular data for leukemia, liver cancer, lymphoma, breast cancer and ovarian cancer. The compendium allows oncology researchers to access data that can identify the most appropriate tumor models. This hope is it will lead to more targeted study design from the beginning that could save time and money before clinical trials begin.

Charles River’s compendium includes models from a wide range tumor subtypes for both in vivo and in vitro oncology research. 

WEBINAR

Webinar: Optimizing Oncology Trials with a ctDNA Test Custom-Built for MRD and Molecular Monitoring

Join this webinar to discover the advantages of using Signatera™ (RUO), a novel assay custom-designed for each patient that detects circulating tumor DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumors.

“The power of our oncology portfolio is stronger than ever,” Birgit Girshick, the company’s EVP for discovery and safety assessment, said in a statement. “Our scientists have worked diligently to accelerate cancer research and anticancer drug development efforts so patients can get the treatments they desperately need.”

Late last month, the CRO announced a partnership deal with Distributed Bio that gives Charles River’s client access to antibody libraries and integrated antibody optimization technologies. Under that agreement, the two will work to develop an end-to-end platform for therapeutic antibody discovery and development.

Suggested Articles

California data analytics company Saama Technologies has raised $40 million as it looks to bolster its artificial technology platform to “disrupt” clinical…

Thermo Fisher Scientific has moved to acquire viral vector developer and manufacturer Brammer Bio for $1.7 billion in cash.

French biotech AlzProtect has teamed up with CRO Parexel for its midstage test of AZP2006 in patients with progressive supranuclear palsy.